---
title: "Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD | CMND Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285210302.md"
description: "Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD | CMND Stock News"
datetime: "2026-05-05T04:50:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285210302.md)
  - [en](https://longbridge.com/en/news/285210302.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285210302.md)
---

# Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD | CMND Stock News

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD | CMND Stock News

### Related Stocks

- [CMND.US](https://longbridge.com/en/quote/CMND.US.md)

## Related News & Research

- [Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down](https://longbridge.com/en/news/286961923.md)
- [Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. | CMND Stock News](https://longbridge.com/en/news/286566409.md)
- [DoctorDerm Unveils Rebrand and Expands Platform with New Prescription Skin and Lash Treatments](https://longbridge.com/en/news/286923716.md)
- [Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial | CMND Stock News](https://longbridge.com/en/news/285936790.md)
- [Cardiff Oncology Wins Buy Rating on Strong Phase 2 Efficacy, FDA-Aligned Phase 3 Path, and Broader Onvansertib Combination Potential](https://longbridge.com/en/news/286478715.md)